Lung Targeted Lipopolymeric Microspheres of Dexamethasone for the Treatment of ARDS

Abstract

Acute respiratory distress syndrome (ARDS), a catastrophic illness of multifactorial etiology, involves a rapid upsurge in inflammatory cytokines that leads to hypoxemic respiratory failure. Dexamethasone, a synthetic corticosteroid, mitigates the glucocorticoid-receptor-mediated inflammation and accelerates tissue homeostasis towards disease resolution. To minimize non-target organ side effects arising from frequent and chronic use of dexamethasone, we designed biodegradable, lung-targeted microspheres with sustained release profiles. Dexamethasone-loaded lipopolymeric microspheres of PLGA (Poly Lactic-co-Glycolic Acid) and DPPC (Dipalmitoylphosphatidylcholine) stabilized with vitamin E TPGS (D-α-tocopheryl polyethylene glycol succinate) were prepared by a single emulsion technique that had a mean diameter of 8.83 ± 0.32 μm and were spherical in shape as revealed from electron microscopy imaging. Pharmacokinetic and biodistribution patterns studied in the lungs, liver, and spleen of Wistar rats showed high selectivity and targeting efficiency for the lung tissue (re 13.98). As a proof-of-concept, in vivo efficacy of the microspheres was tested in the lipopolysaccharide-induced ARDS model in rats. Inflammation markers such as IL-1β, IL-6, and TNF-α, quantified in the bronchoalveolar lavage fluid indicated major improvement in rats treated with dexamethasone microspheres by intravenous route. Additionally, the microspheres substantially inhibited the protein infiltration, neutrophil accumulation and lipid peroxidation in the lungs of ARDS bearing rats, suggesting a reduction in oxidative stress. Histopathology showed decreased damage to the pulmonary tissue upon treatment with the dexamethasone-loaded microspheres. The multipronged formulation technology approach can thus serve as a potential treatment modality for reducing lung inflammation in ARDS. An improved therapeutic profile would help to reduce the dose, dosing frequency and, eventually, the toxicity.

Adenosine Conjugated Docetaxel Nanoparticles—Proof of Concept Studies for Non-Small Cell Lung Cancer

“…The release of DTX was studied from pristine DTX, DPLGA nanoparticles, and ADN-DPLGA nanoparticles by suspending in a Float-A-Lyzer (G2, Spectrum, Repligen, MA, USA) in two different release media, namely phosphate buffer saline pH 7.4 and sodium acetate buffer pH 5.0 containing Tween 80 to maintain sink condition and facilitate release [ 37 ]. The tests were performed at 37 °C (n = 6).…”

Formulation-by-Design of Efinaconazole Spanlastic Nanovesicles for Transungual Delivery Using Statistical Risk Management and Multivariate Analytical Techniques

“…The release of efinaconazole was studied by suspending efinaconazole-loaded spanlastics in a Float-A-Lyzer (G2, Spectrum, Repligen, MA, USA) in phosphate buffer saline pH 7.4. The tests were performed at 37 °C (n = 6) by introducing the dialyzers into 100 mL release media stirred at 100 rpm [ 24 ]. Efinaconazole released at different time intervals up to 4 h was analyzed using the above-mentioned method by withdrawing 0.5 mL of release media.…”

Aerosol Delivery of Surfactant Liposomes for Management of Pulmonary Fibrosis: An Approach Supporting Pulmonary Mechanics

“…The focus of the research has always been the use of nano-carriers for aerosol delivery that will eventually lead to the improved therapeutic efficacy of the drug [4]. However, being a treatment of vital organs, the material-borne toxicity of such carriers should not be overlooked [5].…”